Shares of Onesource Specialty Pharma Ltd dropped nearly 5% on January 31, trading at ₹1,551.15, down ₹74.90 from the previous close of ₹1,626.05. The stock witnessed a day range between ₹1,548.00 and ₹1,616.00, with a market capitalization of ₹61.99 billion. The decline comes amid reports of promoter group entities and TPG affiliates planning to sell shares worth ₹1,200 crore via block deals.
The company recently reported its Q3 FY25 results, showing significant improvement in sales but remaining under pressure due to ongoing losses. Net loss narrowed to ₹68.85 crore in the December quarter from ₹130.16 crore in the same quarter last year. Revenue soared 598.38% YoY to ₹392.56 crore, up from ₹56.21 crore.
Operational metrics improved significantly, with the operating profit margin (OPM) at 36.48%, compared to a negative OPM of -18.68% last year. Profit before depreciation and tax (PBDT) turned positive at ₹102.78 crore, compared to a loss of ₹35.36 crore in the year-ago quarter. Despite these improvements, the company’s net profit remains in the red, reflecting ongoing challenges in achieving profitability.
The ongoing block deal news and mixed earnings performance have contributed to today’s stock decline.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
